December 9, 2014
Tuesday’s RegMed rhythms: volumes are extremely low
December 9, 2014
Histogenics (HGSX) directors and beneficial owners buy shares, exercise/convert options
December 8, 2014
RegMed dints as tax selling motivates ticks lower
December 8, 2014
Monday’s RegMed rhythms: starting the week POSITIVE with slippage as session progresses
December 8, 2014
Histogenics Corp (HSGX) Jumps through the public window successfully at $11
December 3, 2014
Lower open expected; RegMed’s Ocata Therapeutics (OCAT) runs to an open capital market window?
December 1, 2014
Monday’s RegMed rhythms: uncertainty rules and it’s getting ugly
December 1, 2014
Lower open expected; RegMed’s sings the blues as Histogenics seeks public status
November 18, 2014
Organovo (NYSEMKT: ONVO) releases exVive™ Human Liver Tissue
November 11, 2014
Tuesday’s RegMed rhythm – low volume spurs poor performance and sector spasms!
35 companies, 1 interpreter!
Insight, foresight and recommendation
My motto … never leave an investor uninformed! I say today what others won’t, so you can do what others can’t.
My name is Henry McCusker; I endorse these opinions under my own name and with a subscription based membership.
Do you have an opinion you would like to share with us? We would like to hear from you.
Please e-mail us at hwm@regmedinvestors.com.
Editor and Publisher ... Henry McCusker enters his tenth (10th) year at RegMed Investors
© 2026 RegMed Investors (regmedinvestors.com), all rights are reserved.
RegMed Investors (RMi) or Regmedinvestors.com content is the intellectual property of Henry McCusker. Any copying, republication or redistribution of RMI’s content, including by framing or similar means, is expressly prohibited without the prior written consent of Scimitar; who also shall not be liable for any errors or delays in content, or for any actions taken in reliance thereon. For additional information on other Scimitar media services or reposting please email hwm@regmedinvestors.com.
The information included above as well as individual companies and/or securities mentioned should be construed as guidance in RMi reviews.
The facts stated and the opinions given in this publication are based on data and information considered to be reliable and have been carefully worked into my qualitative analyses and prognoses. However, no guarantee can be given as to their fairness, accuracy or completeness.
Henry McCusker, the editor and publisher of RegMed Investors does not hold or have positions in securities referred to in this publication.